|1.||Edvinsson, Lars: 21 articles (08/2015 - 01/2002)|
|2.||Goadsby, Peter J: 19 articles (10/2015 - 03/2004)|
|3.||Salvatore, Christopher A: 15 articles (11/2015 - 10/2006)|
|4.||Kane, Stefanie A: 13 articles (11/2015 - 01/2002)|
|5.||Ho, Tony W: 11 articles (09/2014 - 12/2008)|
|6.||Olesen, Jes: 10 articles (12/2015 - 03/2004)|
|7.||Burgey, Christopher S: 10 articles (11/2015 - 10/2006)|
|8.||Russo, Andrew F: 10 articles (06/2015 - 03/2007)|
|9.||Paone, Daniel V: 9 articles (11/2015 - 09/2007)|
|10.||Messlinger, Karl: 9 articles (01/2013 - 06/2006)|
|1.||Migraine Disorders (Migraine)
03/26/2010 - "Multiple lines of evidence have implicated CGRP in the pathophysiology of migraine headache making the CGRP receptor an attractive target for development of small-molecule antagonists as a novel treatment for this debilitating condition. "
04/01/2005 - "Recent evidence that a CGRP receptor antagonist was effective in the treatment of migraine attack supports the hypothesis that neurogenic vasodilatation is a major underlying mechanism of migraine."
09/01/2015 - "Furthermore, CGRP receptor antagonists may have therapeutic efficacy in the treatment of TMD, as they do with migraine. "
05/01/2014 - "Several CGRP receptor antagonists (CGRP-RAs) were shown to be effective for the acute treatment of migraine, validating the target for the treatment of migraine. "
08/01/2013 - "CGRP receptor antagonists have been developed as novel antimigraine drugs and found to be effective in the treatment of acute migraine attacks. "
12/01/2012 - "Moreover, administration of CGRP receptor antagonists aborts the headache. "
07/01/2010 - "CGRP receptor antagonists will provide an additional and valuable therapeutic option for the treatment of headaches."
12/01/2009 - "Delayed headaches induced by NO may change CGRP or CGRP-receptor expression."
04/01/2009 - "Spinal trigeminal activity was significantly reduced within minutes and to a similar extent as previously reported in animals not treated with NO. Slow continuous NO infusion may be a model of the active headache phase, and inhibition of CGRP receptors can reverse the induced neuronal activity."
03/20/2008 - "Thus, in the trigeminovascular system CGRP receptor localization suggests multiple targets for CGRP in the pathogenesis of primary headaches."
09/01/2009 - "Studies demonstrate that CGRP and CGRP receptors are involved in the transmission and modulation of pain information in peripheral and central nervous system. "
07/01/2009 - "The present results provide evidence for the participation of ionotropic glutamatergic receptors and CGRP receptors in the hyperalgesic responses to exogenous ET-1 and suggest clinically relevant targets for further study of elevated pain caused by release of endogenous ET-1."
11/01/2015 - "Increased mechanosensitivity in OA knees and pain behaviour can be reduced by peripherally acting CGRP receptor antagonists. "
07/16/2015 - "The pain-recipient neurons in the central amygdala expressing CGRP receptors are also critical for establishing a threat memory. "
08/01/2014 - "Our novel finding of CGRP-mediated control of joint nociceptor mechanosensitivity suggests that the CGRP receptor system may be an important target for the modulation of pain during OA. "
11/01/2013 - "CGRP plays a role in protection against ischemia, but CGRP receptor antagonists do not seem to affect this protection to a harmfull extent, when used incidentally as acute antimigraine treatment. "
02/01/2009 - "This dose of CGRP((8-37)), administered either intravenously or intra-atrially, had no effect on ischemia severity or paced LAD flow, indicating no intrinsic effect of CGRP receptor antagonism on the severity of acute myocardial ischemia. "
01/01/2014 - "Finally, using both CGRP(8-37) (a CGRP receptor antagonist) and RP67580 (a SP receptor antagonist) to exclude the confounding effects of neuropeptides, we confirmed aforementioned detrimental effects as TRPV1(-/-) mouse hearts exhibited improved cardiac function during ischemia/reperfusion. "
12/06/2005 - "The hearts of gene-targeted TRPV1-null mutant (TRPV1(-/-)) mice or wild-type (WT) mice were perfused in a Langendorff apparatus in the presence or absence of capsazepine (a TRPV1 receptor antagonist), CGRP, CGRP(8-37) (a CGRP receptor antagonist), SP, or RP67580 (a neurokinin-1 [NK1] receptor antagonist) when hearts were subjected to 40 minutes of ischemia and 30 minutes of reperfusion. "
09/01/2007 - "Hearts of gene-targeted TRPV1-null mutant (TRPV1(-/-)) or wild-type (WT) mice were Langendorffly perfused in the presence or absence of CGRP(8-37), a selective calcitonin gene-related peptide (CGRP) receptor antagonist; or RP-67580, a selective neurokinin-1 receptor antagonist when hearts were subjected to three 5-min periods of ischemia PC followed by 30 min of global ischemia and 40 min of reperfusion (I/R). "
|5.||Cluster Headache (Cluster Headaches)
01/01/2011 - "CGRP and VIP have been found at increased concentrations in jugular venous plasma during attacks of migraine or cluster headache, and CGRP receptor antagonists have recently been shown to be effective in migraine therapy. "
08/01/2004 - "The data suggest that there are non-presynaptic CGRP receptors in the trigeminocervical complex that can be inhibited by CGRP receptor blockade and that a CGRP receptor antagonist would be effective in the acute treatment of migraine and cluster headache."
|1.||Calcitonin Gene-Related Peptide
|3.||N- (6- (2,3- difluorophenyl)- 2- oxo- 1- (2,2,2- trifluoroethyl)azepan- 3- yl)- 4- (2- oxo- 2,3- dihydro- 1H- imidazo(4,5- b)pyridin- 1- yl)piperidine- 1- carboxamide
|5.||Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)
|6.||Nitric Oxide Synthase (NO Synthase)
|9.||calcitonin gene-related peptide (8-37)